Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Myopic defocus" refers to a retinal image condition where light rays are focused in front of the retina, causing distance vision to be blurred. It can be induced experimentally or therapeutically (e.g., with positive lenses) to trigger a cascade of retinal signaling pathways that suppress ocular axial elongation, thereby slowing the progression of myopia. It is a critical concept in understanding the feedback control of postnatal eye growth (emmetropization) and is the basis for optical strategies to prevent or reduce the worsening of nearsightedness. However, it is not itself a molecule, receptor, or direct therapeutic target, but an optical/biophysical phenomenon that influences biological processes through the retina.
Inducing "myopic defocus" (i.e., presenting a blurred image where the light focuses in front of the retina, such as with positive lens wear) suppresses axial eye growth through retinal signaling pathways that ultimately decrease myopia progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myopic defocus.